Mark Pollack to Monoamine Oxidase Inhibitors
This is a "connection" page, showing publications Mark Pollack has written about Monoamine Oxidase Inhibitors.
Connection Strength
0.838
-
WCA recommendations for the long-term treatment of panic disorder. CNS Spectr. 2003 Aug; 8(8 Suppl 1):17-30.
Score: 0.236
-
The pharmacotherapy of social phobia. Int Clin Psychopharmacol. 1996 Jun; 11 Suppl 3:71-5.
Score: 0.143
-
The pharmacotherapy of panic disorder. Bull Menninger Clin. 1996; 60(2 Suppl A):A54-75.
Score: 0.139
-
The pharmacotherapy of panic disorder. J Clin Psychiatry. 2005; 66 Suppl 4:23-7.
Score: 0.065
-
WCA Recommendations for the long-term treatment of posttraumatic stress disorder. CNS Spectr. 2003 Aug; 8(8 Suppl 1):31-9.
Score: 0.059
-
WCA recommendations for the long-term treatment of social phobia. CNS Spectr. 2003 Aug; 8(8 Suppl 1):40-52.
Score: 0.059
-
Social anxiety disorder: designing a pharmacologic treatment strategy. J Clin Psychiatry. 1999; 60 Suppl 9:20-6.
Score: 0.043
-
Moclobemide in social phobia: a controlled dose-response trial. J Clin Psychopharmacol. 1997 Aug; 17(4):247-54.
Score: 0.039
-
Integrated treatment of panic disorder. Bull Menninger Clin. 1995; 59(2 Suppl A):A4-26.
Score: 0.032
-
Management of antidepressant-induced side effects: a practical guide for the clinician. J Clin Psychiatry. 1987 Jan; 48(1):3-8.
Score: 0.019
-
Orthostatic hypotension and antidepressant pharmacotherapy. Psychopharmacol Bull. 1987; 23(1):182-6.
Score: 0.005